Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 131 | 51% |
| 2020 | 2 | 135 | 53% |
| 2021 | 4 | 176 | 57% |
| 2022 | 3 | 166 | 60% |
| 2023 | 0 | 116 | 64% |
| 2024 | 0 | 115 | 66% |
| 2025 from claims | – | 64 52–76 | 67% |
| 2026 forecast | – | 67 52–84 | 66% |
| 2027 forecast | – | 68 50–89 | 66% |
| 2028 forecast | – | 68 48–94 | 67% |
| 2029 forecast | – | 69 47–99 | 67% |
| 2030 forecast | – | 70 46–103 | 67% |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2024, 100% surgery center.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 42 | 3,504−3.3%/yr | −3.3%/yr | 1.9 | 48% | 3,660 in 2030+0.7%/yr |
| Pennsylvania | 45 | 3,182−0.1%/yr | −0.1%/yr | 2.4 | 49% | 3,020 in 2030−0.9%/yr |
| New Jersey | 23 | 1,908−1.3%/yr | −1.3%/yr | 1.8 | 56% | 1,990 in 2030+0.7%/yr |
| Massachusetts | 29 | 1,871−4.2%/yr | −4.2%/yr | 2.0 | 38% | 2,190 in 2030+2.6%/yr |
| Connecticut | 6 | 441−6.9%/yr | −6.9%/yr | 1.3 | 97% | 470 in 2030+1.1%/yr |
| Maine | 5 | 254−4%/yr | −4%/yr | 1.6 | 100% | 240 in 2030−1.2%/yr |
| New Hampshire | 3 | 201+0.6%/yr | +0.6%/yr | 0.9 | 89% | 290 in 2030+6.5%/yr |
| Vermont | 2 | 101+27%/yr | +27%/yr | 0.9 | 0% | 180 in 2030+9.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 27 | 7,5280%/yr | 0%/yr | 80.91.7× | 89% | 11,900 in 2030+7.9%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with New York
Alcon leads with 23% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 10 companies reported engagement with Rhode Island’s surgeons worth $35K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.